These behavioural improvements are likely underpinned by the observed reduction in amyloid plaque burden and normalisation of key molecular markers, including increased Bdnf expression, upregulation of the mitochondrial regulator Irs2, and modulation of insulin receptor-related pathways. This evidence concerns the gene IRS2 and amyloidosis.